Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author does not hold a position in RXRX.
← Back to Free Index

RXRX

Analysis as of: 2026-08-28
Recursion Pharmaceuticals, Inc.
Clinical-stage biotech using an AI-native lab-and-data platform to discover drug candidates internally and with pharma partners.
ai automation biotech healthcare
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Proof gates before a real revenue mix shift
The setup is attractive if clinical proof starts turning a differentiated discovery engine into owned product economics and deeper downstream partner capture. The opportunity is real, but the rerating still depends more on a short list of proof gates than on AI enthusiasm alone.

Analysis

Thesis
Recursion can rerate from an AI-biotech narrative into an early medicine engine if REC-4881 gets an approval-oriented path, one additional internal program shows credible human proof, and the company monetizes its data-and-lab loop through a better mix of product, milestone, royalty, and standardized external discovery revenue.
Last Economy Alignment
Cheaper cognition helps Recursion because it owns the scarce layer: proprietary wet-lab data, automated experimentation, and clinical assets. The cap on the score is that value still has to pass through slow human proof and regulators.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
4.1x (from 5 most recent analyses)
Reasoning
The upside is a mix-shift story, not just an AI story. If one rare-disease asset becomes commercially credible, a second internal program validates repeatability, and partner economics deepen from discovery fees into milestones and royalties, the business can look less like lumpy outsourced R&D and more like an emerging multi-asset medicine company with a differentiated discovery engine.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The main risk is not whether Recursion can generate more AI output; it is whether that output becomes repeatable human and regulatory proof before financing leverage weakens. REC-4881 path clarity is the first gate, a second internal proof asset is the next gate, and both matter more than another incremental model or workflow improvement.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.58
They control proprietary lab data, workflow software, and clinical assets, so cheaper AI can make their discovery engine more valuable rather than replace it. The catch is that biology and regulators still decide whether that advantage becomes real revenue.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$7.22
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case